Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting

Executive Summary

During its July 2016 meeting, the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended approval for two anticancers, cabozantinib and lenvatinib, that will likely shake up the advanced kidney cancer sector, and a new therapy for pancreatic cancer, liposomal and pegylated irinotecan.

Advertisement

Related Content

Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown
Eisai Predicts "Mayhem" For Kisplyx After NICE Finally Okays Halaven
Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market
Meek To Drive M&A At Ipsen, Building On Two Major Launches
Value Measures, Side Effects Help Differentiate Drugs In Crowded Kidney Cancer Market
Eisai Taps Novartis Oncology Firepower For Lenvima
Exelixis’ Cabozantinib Cleared For Kidney Cancer, With Competitive Labeling
Ipsen Pays Exelixis $200m Up Front For Ex-US Cometriq Rights
Bristol Gets First Mover-Advantage, Again, With Opdivo Kidney Cancer Approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel